Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Celcuity, and Corbus Pharmaceuticals. According to TipRanks, McCammon has an average return of 88.0% and a 64.91% success rate on recommended stocks.
Inhibrx Biosciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $277.50.
Based on Inhibrx Biosciences Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $33.44 million. In comparison, last year the company had a GAAP net loss of $43.31 million
